Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.

Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U.

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13.

2.

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.

Mross K, Richly H, Frost A, Scharr D, Nokay B, Graeser R, Lee C, Hilbert J, Goeldner RG, Fietz O, Scheulen ME.

Cancer Chemother Pharmacol. 2016 Aug;78(2):405-17. doi: 10.1007/s00280-016-3095-6. Epub 2016 Jun 27.

3.

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.

Mross K, Büchert M, Frost A, Medinger M, Stopfer P, Studeny M, Kaiser R.

BMC Cancer. 2014 Jul 11;14:510. doi: 10.1186/1471-2407-14-510.

4.

FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.

Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sörgel F, Jaehde U, Burkholder I, Moritz B, Büchert M.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):642-52. doi: 10.5414/CP202109.

PMID:
24800922
5.

First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.

Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A, Gille H, Audoly LP, Scheulen ME.

PLoS One. 2013 Dec 13;8(12):e83232. doi: 10.1371/journal.pone.0083232. eCollection 2013.

6.

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.

Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB.

Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13.

7.

Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.

Kanefendt F, Lindauer A, Mross K, Fuhr U, Jaehde U.

J Pharm Biomed Anal. 2012 Nov;70:485-91. doi: 10.1016/j.jpba.2012.06.039. Epub 2012 Jul 4.

PMID:
22819208
8.

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME.

Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14.

9.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K.

Br J Cancer. 2012 May 22;106(11):1722-7. doi: 10.1038/bjc.2012.153. Epub 2012 May 8.

10.

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O.

Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15.

11.

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G.

Curr Oncol. 2012 Feb;19(1):e28-35. doi: 10.3747/co.19.866.

12.

Palliative treatment: anticancer, antisymptom, or end-of-life care?

Arends J, Mross K, Pletschen L, Azémar M.

J Clin Oncol. 2011 Dec 1;29(34):4591; author reply 4591-2. doi: 10.1200/JCO.2011.38.9635. Epub 2011 Oct 31. No abstract available.

PMID:
22042937
13.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.

Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, Fasol U, Büchert M, Krätzschmer J, Delesen H, Rajagopalan P, Christensen O.

Vasc Cell. 2011 Jul 29;3:16. doi: 10.1186/2045-824X-3-16.

14.

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.

Fasol U, Frost A, Büchert M, Arends J, Fiedler U, Scharr D, Scheuenpflug J, Mross K.

Ann Oncol. 2012 Apr;23(4):1030-6. doi: 10.1093/annonc/mdr300. Epub 2011 Jun 21.

15.

A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.

Mross K, Büchert M, Fasol U, Jaehde U, Kanefendt F, Strumberg D, Arends J, Hense J, Moritz B, Fischer R, Scheulen ME.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):96-8. No abstract available.

PMID:
21176744
16.

Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

Kanefendt F, Lindauer A, Kinzig M, Strumberg D, Scheulen ME, Mross K, Fischer R, Moritz B, Sörgel F, Jaehde U.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):88-90. No abstract available.

PMID:
21176741
17.

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Invest New Drugs. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21.

PMID:
21170759
18.

A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.

Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D, Laurent D.

Anticancer Res. 2010 Jun;30(6):2335-9.

PMID:
20651389
19.

Clinical trials with anti-angiogenic agents in hematological malignancies.

Medinger M, Mross K.

J Angiogenes Res. 2010 Jun 22;2:10. doi: 10.1186/2040-2384-2-10.

20.

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):473-5. No abstract available.

PMID:
20557849
21.

c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis.

Medinger M, Kleinschmidt M, Mross K, Wehmeyer B, Unger C, Schaefer HE, Weber R, Azemar M.

Pathol Oncol Res. 2010 Sep;16(3):295-301. doi: 10.1007/s12253-010-9247-9. Epub 2010 Feb 23.

22.

First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.

Unger C, Berdel W, Hanauske AR, Sindermann H, Engel J, Mross K.

Eur J Cancer. 2010 Mar;46(5):920-5. doi: 10.1016/j.ejca.2009.12.028. Epub 2010 Jan 14.

PMID:
20079628
23.

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R.

Clin Cancer Res. 2010 Jan 1;16(1):311-9. doi: 10.1158/1078-0432.CCR-09-0694. Epub 2009 Dec 22.

24.

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.

Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, Unger C, Blum H, Hennig J, Milenkova TP, Tessier J, Krebs AD, Ryan AJ, Fischer R.

J Angiogenes Res. 2009 Sep 21;1:5. doi: 10.1186/2040-2384-1-5.

25.

Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer.

Steinbild S, Frost A, Häring B, Unger C, Mross K.

Onkologie. 2009 Sep;32(8-9):488-92. doi: 10.1159/000226137. Epub 2009 Jul 23.

PMID:
19745592
26.

Uptake of permethrin from impregnated clothing.

Rossbach B, Appel KE, Mross KG, Letzel S.

Toxicol Lett. 2010 Jan 15;192(1):50-5. doi: 10.1016/j.toxlet.2009.06.863. Epub 2009 Jul 1.

PMID:
19576275
27.

First-in-man and first-of-class-in-man clinical trials in oncology.

Mross K.

Int J Clin Pharmacol Ther. 2009 Jan;47(1):68-70. No abstract available.

PMID:
19203543
28.

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Strumberg D, Schultheis B, Adamietz IA, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen ME, Mross K.

Br J Cancer. 2008 Nov 18;99(10):1579-85. doi: 10.1038/sj.bjc.6604724.

29.

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G.

J Clin Oncol. 2008 Dec 1;26(34):5511-7. doi: 10.1200/JCO.2008.16.1547. Epub 2008 Oct 27.

PMID:
18955456
30.

[Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].

Mross K.

Pharm Unserer Zeit. 2008;37(5):404-15. doi: 10.1002/pauz.200800281. Review. German. No abstract available.

PMID:
18729270
31.

Risk assessment of Bundeswehr (German Federal Armed Forces) permethrin-impregnated battle dress uniforms (BDU).

Appel KE, Gundert-Remy U, Fischer H, Faulde M, Mross KG, Letzel S, Rossbach B.

Int J Hyg Environ Health. 2008 Mar;211(1-2):88-104. doi: 10.1016/j.ijheh.2007.10.005. Epub 2008 Jan 28. Review.

PMID:
18222725
32.

Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

Steinbild S, Arends J, Medinger M, Häring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K.

Onkologie. 2007 Dec;30(12):629-35. Epub 2007 Nov 30.

PMID:
18063875
33.

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D, Hochhaus A, Hanauske AR, Edler L, Burkholder I, Scheulen M.

Br J Cancer. 2007 Dec 3;97(11):1480-5. Epub 2007 Nov 27.

34.

Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.

Unger C, Häring B, Medinger M, Drevs J, Steinbild S, Kratz F, Mross K.

Clin Cancer Res. 2007 Aug 15;13(16):4858-66.

35.

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C.

J Clin Oncol. 2007 Jul 20;25(21):3045-54.

PMID:
17634482
36.

Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.

Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A.

Clin Pharmacol Ther. 2007 Jan;81(1):76-82.

PMID:
17186002
37.

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, Brendel E, Christensen O, Unger C.

Eur J Cancer. 2007 Jan;43(1):55-63. Epub 2006 Nov 13.

PMID:
17095207
38.

PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.

Mross K, Holländer N, Frost A, Unger C, Ziroli V, Massing U.

Onkologie. 2006 Oct;29(10):444-50. Epub 2006 Sep 27.

PMID:
17028453
39.

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.

Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S.

Eur J Cancer. 2006 Nov;42(17):2893-6. Epub 2006 Sep 6.

40.

Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.

Frost A, Gmehling D, Azemar M, Unger C, Mross K.

Onkologie. 2006 Jul;29(7):314-8. Epub 2006 Jul 3.

PMID:
16874015
41.

Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications.

Mross K, Holländer N, Unger C, Massing U.

Int J Clin Pharmacol Ther. 2005 Dec;43(12):601-2. No abstract available.

PMID:
16372534
42.

Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen.

Mielke S, Sparreboom A, Behringer D, Mross K.

Anticancer Res. 2005 Nov-Dec;25(6C):4423-7.

43.

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.

Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod HL.

Clin Cancer Res. 2005 Nov 15;11(22):8097-104.

44.

Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.

Mielke S, Sparreboom A, Mross K.

Eur J Cancer. 2006 Jan;42(1):24-30. Epub 2005 Nov 15. Review.

PMID:
16293411
45.

Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.

Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K.

Clin Cancer Res. 2005 Jul 1;11(13):4843-50.

46.

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L.

J Clin Oncol. 2005 Aug 10;23(23):5314-22. Epub 2005 Jun 13.

PMID:
15955899
47.

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C.

Eur J Cancer. 2005 Jun;41(9):1291-9.

PMID:
15939265
48.

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.

Serin D, Verrill M, Jones A, Delozier T, Coleman R, Kreuser ED, Mross K, Longerey B, Brandely M.

Br J Cancer. 2005 Jun 6;92(11):1989-96.

49.

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marmé D.

Ann Oncol. 2005 Apr;16(4):558-65. Epub 2005 Feb 10.

50.

[Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].

Medinger M, Steinbild S, Mross K.

Praxis (Bern 1994). 2004 Sep 29;93(40):1633-44. Review. German.

PMID:
15495753

Supplemental Content

Support Center